세팔로스포린 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of cephalosporin Market

The global cephalosporin market is demonstrating steady growth, supported by the increasing burden of bacterial infections and the rising demand for broad-spectrum antibiotics. The market was valued at USD 8.32 billion in 2025 and is projected to grow to USD 8.73 billion in 2026, reaching USD 13.62 billion by 2034, registering a CAGR of 5.72% during the forecast period. North America dominated the market with a 47.05% share in 2025, driven by advanced healthcare infrastructure and high prescription volumes.

Cephalosporins are B-lactam antibiotics that inhibit bacterial cell wall synthesis, leading to bacterial cell death. These antibiotics are widely used to treat infections such as urinary tract infections, respiratory infections, skin and soft tissue infections, pneumonia, and meningitis. The continuous emergence of antimicrobial resistance (AMR) has accelerated the development of newer-generation cephalosporins with enhanced efficacy against resistant strains.

Market Dynamics

Market Drivers

The increasing number of new product launches by key pharmaceutical players is a major driver of market growth. Rising antibiotic resistance has compelled companies to invest heavily in R&D to develop advanced cephalosporins such as ceftaroline and ceftobiprole, which are effective against multidrug-resistant bacteria.

For instance, in April 2024, Basilea Pharmaceutica Ltd received U.S. FDA approval for ZEVTERA (ceftobiprole) for bloodstream infections, acute bacterial skin infections, and community-acquired bacterial pneumonia. Such approvals significantly boost market demand.

Market Restraints

The market growth is restrained by adverse effects associated with cephalosporins, including gastrointestinal complications and allergic reactions. Moreover, reports of neurotoxicity, particularly among elderly patients and those receiving high intravenous doses, have raised safety concerns.

In March 2023, New Zealand's Medicines Adverse Reaction Committee highlighted neurological side effects such as seizures and encephalopathy, prompting cautious prescription practices and limiting widespread adoption.

Market Opportunities

Advancements in drug delivery systems and nanoparticle-based formulations present significant growth opportunities. Research studies are focusing on converting older-generation cephalosporins into nano-antibiotics using gold and silver nanoparticles to improve potency, reduce dosage frequency, and overcome resistance.

In January 2023, an NIH study demonstrated that ineffective cephalosporins could be transformed into potent nano-antibiotics using gold nanoparticles, offering a promising avenue for market expansion.

Market Challenges

Strict regulatory frameworks aimed at controlling AMR pose a major challenge. Governments worldwide are enforcing antibiotic stewardship programs to restrict overuse.

For example, in October 2024, the Indian Council of Medical Research (ICMR) reported high resistance levels among UTI-causing pathogens against third-generation cephalosporins, emphasizing the need for controlled prescribing.

Cephalosporin Market Trends

A key market trend is the rising popularity of combination therapies, where cephalosporins are used alongside B-lactamase inhibitors to improve clinical outcomes against resistant infections. Additionally, the growing preference for injectable formulations due to faster action and targeted delivery is shaping production strategies.

In June 2024, Sands Active Ltd. launched a cephalosporin injectable manufacturing plant in Sri Lanka, highlighting this trend.

Segmentation Analysis

By generation, the third-generation cephalosporins segment is expected to dominate due to its broad-spectrum activity and widespread use in respiratory and skin infections.

By route of administration, the oral segment is projected to grow significantly due to ease of use and rising self-medication, while the parenteral segment shows strong growth driven by hospital demand.

By disease indication, urinary tract infections hold the largest share, supported by the rising prevalence of hospital-acquired UTIs.

By distribution channel, hospital pharmacies dominate due to high prescription volumes.

Regional Outlook

North America led the market with a valuation of USD 3.89 billion in 2025 and USD 4.09 billion in 2026, driven by high rates of hospital-acquired infections.

Europe holds the second-largest share due to increased consumption of second- and third-generation cephalosporins.

Asia Pacific is expected to register the highest CAGR, supported by large-scale API production and rising healthcare investments.

Latin America and the Middle East & Africa are anticipated to witness moderate growth owing to improving regulatory frameworks and manufacturing capacity expansion.

Competitive Landscape

The market is semi-consolidated, with key players including Pfizer Inc., Sandoz Group AG, Merck & Co., Inc., AbbVie Inc., GSK plc., Astellas Pharma Inc., and Shionogi & Co., Ltd. These companies focus on R&D investments, strategic collaborations, and capacity expansion to strengthen their market presence.

Conclusion

The global cephalosporin market is expected to grow steadily through 2034, driven by rising bacterial infections, continuous product innovations, and the urgent need to combat antimicrobial resistance. Although adverse effects and strict regulatory controls pose challenges, advancements in combination therapies, nanoparticle-based drug delivery, and injectable formulations are creating new growth opportunities. With North America maintaining dominance and Asia Pacific emerging as a high-growth region, the cephalosporin market is well-positioned for sustained expansion, reinforcing its critical role in modern infectious disease management.

Segmentation

By Generation

• First Generation
• Second Generation
• Third Generation
• Fourth Generation
• Others

By Route of Administration

• Oral
• Parenteral

By Disease Indications

• Urinary Tract Infections
• Skin & Soft Tissue infection
• Respiratory Infections
• Meningitis
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
  • U.S.
  • Canada
• Europe (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Pipeline Analysis, By Key Players
• 4.2. Overview of Antimicrobial Treatment Guidelines
• 4.3. Overview of the Antibiotic resistant "Priority Pathogens" Published by WHO
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.5. New Product Launches, By Key Players

5. Global Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Generation
  • 5.1.1. First Generation
  • 5.1.2. Second Generation
  • 5.1.3. Third Generation
  • 5.1.4. Fourth Generation
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Parenteral
• 5.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.3.1. Urinary Tract Infections
  • 5.3.2. Skin & Soft Tissue Infections
  • 5.3.3. Respiratory Infections
  • 5.3.4. Meningitis
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacy
  • 5.4.2. Retail Pharmacy
  • 5.4.3. Online Pharmacy
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Generation
  • 6.1.1. First Generation
  • 6.1.2. Second Generation
  • 6.1.3. Third Generation
  • 6.1.4. Fourth Generation
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Parenteral
• 6.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.3.1. Urinary Tract Infections
  • 6.3.2. Skin & Soft Tissue Infections
  • 6.3.3. Respiratory Infections
  • 6.3.4. Meningitis
  • 6.3.5. Others
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacy
  • 6.4.2. Retail Pharmacy
  • 6.4.3. Online Pharmacy
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Generation
  • 7.1.1. First Generation
  • 7.1.2. Second Generation
  • 7.1.3. Third Generation
  • 7.1.4. Fourth Generation
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Parenteral
• 7.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.3.1. Urinary Tract Infections
  • 7.3.2. Skin & Soft Tissue Infections
  • 7.3.3. Respiratory Infections
  • 7.3.4. Meningitis
  • 7.3.5. Others
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacy
  • 7.4.2. Retail Pharmacy
  • 7.4.3. Online Pharmacy
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Generation
  • 8.1.1. First Generation
  • 8.1.2. Second Generation
  • 8.1.3. Third Generation
  • 8.1.4. Fourth Generation
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Parenteral
• 8.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.3.1. Urinary Tract Infections
  • 8.3.2. Skin & Soft Tissue Infections
  • 8.3.3. Respiratory Infections
  • 8.3.4. Meningitis
  • 8.3.5. Others
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacy
  • 8.4.2. Retail Pharmacy
  • 8.4.3. Online Pharmacy
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Generation
  • 9.1.1. First Generation
  • 9.1.2. Second Generation
  • 9.1.3. Third Generation
  • 9.1.4. Fourth Generation
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Oral
  • 9.2.2. Parenteral
• 9.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.3.1. Urinary Tract Infections
  • 9.3.2. Skin & Soft Tissue Infections
  • 9.3.3. Respiratory Infections
  • 9.3.4. Meningitis
  • 9.3.5. Others
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacy
  • 9.4.2. Retail Pharmacy
  • 9.4.3. Online Pharmacy
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Generation
  • 10.1.1. First Generation
  • 10.1.2. Second Generation
  • 10.1.3. Third Generation
  • 10.1.4. Fourth Generation
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Oral
  • 10.2.2. Parenteral
• 10.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.3.1. Urinary Tract Infections
  • 10.3.2. Skin & Soft Tissue Infections
  • 10.3.3. Respiratory Infections
  • 10.3.4. Meningitis
  • 10.3.5. Others
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacy
  • 10.4.2. Retail Pharmacy
  • 10.4.3. Online Pharmacy
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Pfizer Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Sandoz Group AG
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merck & Co., Inc.,
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. AbbVie Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Bayer AG
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Astellas Pharma Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Shionogi & Co., Ltd
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Abbott
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)